Physicians at the Miami Cancer Institute will have access to the startup’s Cota Nodal Address system, which categorizes clinical and genomic data based on demographics, diseases and intended therapies for similar patients.
Miami Cancer Institute officials hope the product will help clinicians inform and personalize cancer care.
“With the ability to see genomic-level data alongside cost and historical clinical data, Cota will help accelerate our journey to value-based care,” said Leonard Kalman, MD, executive deputy director and CMO of Miami Cancer Institute.
More articles on data analytics & precision medicine:
23andMe launches genomics study focused on diet, exercise
Microsoft, Google venture arms invest in genomic information startup DNAnexus
4 questions with PotentiaMetrics CEO Robert Palmer on personalized healthcare
